MedTrace Logo

Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain

NCT06613737 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-04-23

Study results available
· View outcomes & findings →

Summary

An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a New Influenza A H3N2 Challenge Strain in Healthy Participants 18 to 55 Years of Age

In Part A, up to 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2).

Based on the outcome of Part A, participants in Part B, may be given Virus Dose 1, Virus Dose 2, or another virus dose (e.g., Virus Dose 3)

Conditions

  • Influenza A H3N2

Interventions

OTHER

Influenza A H3N2 virus dose arm 1

Medium dose, approximately 10\^4.5 TCID50/mL

OTHER

Influenza A H3N2 virus dose arm 2

High dose, approximately 10\^5.5 TCID50/mL

OTHER

Influenza A H3N2 virus dose arm 3

TBD, depending on outcome of Part A

Sponsors & Collaborators

  • Hvivo

    lead INDUSTRY

Principal Investigators

  • Alexandre Lima, MD-PhD · hVIVO Services Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-11
Primary Completion
2025-03-10
Completion
2025-03-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06613737 on ClinicalTrials.gov